Patent ID: 8633208

Claim:
A method for the treatment of depression, comprising administering a compound of formula (I), a pharmaceutically acceptable salt or solvate thereof, as the sole active agent to treat depression to a subject in need of treatment: wherein: X is independently selected from —CH group or a nitrogen atom (—N); W is independently selected from an aryl group, an heteroaryl or an heteroaryl group of Heteroaryl group of Formula II: wherein said aryl group is an unsubstituted or substituted phenyl, with one or more substituents independently selected from a halogen selected from the group consisting of fluorine (—F), chlorine (—Cl) and bromine (—Br), trifluoromethyl (—CF 3 ), alkyl, hydroxyl (—OH), alkoxy, trifluoromethoxy (—OCF 3 ), cyano (—CN), carboxamido selected from the group consisting of —CONHR 3 , —NHCOR 3 , —CONR 2 R 3 and —NR 2 COR 3 , carbonyl, alkylthio, thiol, sulfinyl and sulfonyl wherein R 2 and R 3 are as defined below; when W is an heteroaryl group it is independently selected from the following penta- or hexa-atomic heterocycles: 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, pyrrole-2-yl, pyrrole-3-yl, pyridine-4-yl, pyridine-3-yl, pyrimidin-4-yl, wherein the heterocyclic ring may be substituted with one or two substituents independently selected from: R 1 , alkoxy or hydroxy (—OH), wherein R 1 and R 2 are as defined below; when W is an heteroaryl group of formula II, it is a benzocondensed-5 or -6 membered heterocycle, wherein: Z and Y are independently selected from: an oxygen atom (—O—), a sulphur atom (—S—), or the groups: —CHR 3 —, —CR 3 ═, —NH—, —N═; Q is independently selected from the groups: —CHR 3 —, —CH═, —CR 3 ═, —CHR 3 —CH 2 —; provided that the combination of Y, Z, Q groups give rise to: 1,3-benzodioxole, benzofuran, 2,3-dihydrobenzofuran, benzothiophene, 2,3-dihydrobenzothiophene, indole, 2,3-dihydroindole, benzimidazole, benzoxazole, benzothiazole, 2H-3,4-dihydrobenzopyran, [1,4]-benzodioxine, 2,3-dihydro-[1,4]-benzodioxine (1,4-benzodioxan); R 1 is independently selected from hydrogen (—H) or C 1 -C 4 alkyl or hydroxymethyl (—CH 2 OH), aminomethyl (—CH 2 NH 2 ), alkylaminomethyl, di-alkylaminomethyl, trifluoromethyl (—CF 3 ); the C 1 -C 4 alkyl group is a linear or branched saturated or unsaturated C 1 -C 4 hydrocarbon chain; provided that in compounds of formula (I) not more than two R 1 groups substituting the imidazole ring, are simultaneously C 1 -C 4 alkyl or trifluoromethyl (—CF 3 ) and only one R 1 group is hydroxymethyl (—CH 2 OH), aminomethyl (—CH 2 NH 2 ) alkylaminomethyl, di-alkylaminomethyl; R 2 is a C 1 -C 6 alkyl chain; herein the C 1 -C 6 alkyl chain is intended as above defined for C 1 -C 4 but optionally substituted with an aryl, aryl being herein as defined above; R 3 is independently selected from hydrogen, C 1 -C 4 alkyl as defined above for R 1 ; including all the possible tautomers of compounds of formula (I).